About this item:
156 Views | 107 Downloads
Author Notes:
Address for Correspondence: Andreas P. Kalogeropoulos MD MPH PhD, Emory Clinical Cardiovascular Research Institute, 1462 Clifton Road, NE, Suite 535B, Atlanta, GA 30322, Telephone #: (404) 778-3630; Fax #: (404) 778-5285, akaloge@emory.edu
There are no conflicts of interest associated with this work.
The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Subject:
Research Funding:
This study was supported in part by the National Center for Advancing Translational Sciences of the National Institutes of Health under Award Number UL1TR000454.
Keywords:
- Science & Technology
- Life Sciences & Biomedicine
- Cardiac & Cardiovascular Systems
- Cardiovascular System & Cardiology
- Inotropic agents
- heart failure
- mortality
- ARTERY CATHETERIZATION EFFECTIVENESS
- NATRIURETIC PEPTIDE
- TERM OUTCOMES
- DOUBLE-BLIND
- DOBUTAMINE
- TRIAL
- AGENTS
- LEVOSIMENDAN
- ARRHYTHMIAS
- NESIRITIDE
Inotrope Use and Outcomes Among Patients Hospitalized for Heart Failure: Impact of Systolic Blood Pressure, Cardiac Index, and Etiology
Abstract:
Background Inotropes are widely used in hospitalized systolic heart failure (HF) patients, especially those with low systolic blood pressure (SBP) or cardiac index. In addition, inotropes are considered to be harmful in nonischemic HF. Methods and Results We examined the association of in-hospital inotrope use with (1) major events (death, ventricular assist device, or heart transplant) and (2) study days alive and out of hospital during the first 6 months in the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness, which excluded patients with immediate need for inotropic therapy. Predefined subgroups of interest were baseline SBP <100 versus ≥100 mm Hg, cardiac index <1.8 vs ≥1.8 L min-1 m -2, and ischemic versus nonischemic HF etiology. Inotropes were frequently used in both the <100 mm Hg (88/165 [53.3%]) and the ≥100 mm Hg (106/262 [40.5%]) SBP subgroups and were associated with higher risk for major events in both subgroups (adjusted hazard ratio [HR] 2.85, 95% confidence interval [CI] 1.59-5.12 [P <.001]; and HR 1.86, 95% CI 1.02-3.37 [P =.042]; respectively). Risk with inotropes was more pronounced among those with cardiac index ≥1.8 L min-1 m-2 (n = 114; HR 4.65, 95% CI 1.98-10.9; P <.001) vs <1.8 L min-1 m-2 (n = 82; HR 1.48, 95% CI 0.61-3.58; P =.39). Event rates were higher with inotropes in both ischemic (n = 215; HR 2.64, 95% CI 1.49-4.68; P =.001) and nonischemic (n = 216; HR 2.19, 95% CI 1.18-4.07; P =.012) patients. Across all subgroups, patients who received inotropes spent fewer study days alive and out of hospital. Conclusions In the absence of cardiogenic shock or end-organ hypoperfusion, inotrope use during hospitalization for HF was associated with unfavorable 6-month outcomes, regardless of admission SBP, cardiac index, or HF etiology.
Copyright information:
© 2014 Elsevier Inc. All rights reserved.
This is an Open Access work distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (http://creativecommons.org/licenses/by-nc-nd/4.0/).
